ORKAMBI (LUMACAFTOR & IVACAFTOR) TABLETS

ORKAMBI is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 2 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene.

It may help to improve breathing, reduce the risk of lung infections, and improve weight gain.

Orkambi (Lumacaftor & Ivacaftor) Tablets suppliers in India. Allevaire India New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

SOURCING:

Alleviare Life Sciences connects the buyer with the supplier who can ship Orkambi (Lumacaftor & Ivacaftor) (Cancer Treatment Medicines) to any country of the world as per the buyer’s requirement and Government regulations of the country.

Alleviare Life Sciences provides options for choosing exporter and supplier of Cancer treatment Medicines We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

The order for Orkambi (Lumacaftor & Ivacaftor) Tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14):

Genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.

Genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.

Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

Medicine Name: Orkambi
Generic Name: Lumacaftor & Ivacaftor
Approval Date: July 2018
Company Name: Vertex Pharmaceuticals Incorporated